Feasibility and Safety of Hydrogen Gas Inhalation for Post-Cardiac Arrest Syndrome　– First-in-Human Pilot Study

Background:Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of post-cardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied.Methods and Results:Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital card...

Full description

Saved in:
Bibliographic Details
Published inCirculation Journal Vol. 80; no. 8; pp. 1870 - 1873
Main Authors Tamura, Tomoyoshi, Hayashida, Kei, Sano, Motoaki, Suzuki, Masaru, Shibusawa, Takayuki, Yoshizawa, Joe, Kobayashi, Yosuke, Suzuki, Takeshi, Ohta, Shigeo, Morisaki, Hiroshi, Fukuda, Keiichi, Hori, Shingo
Format Journal Article
LanguageEnglish
Published Japan The Japanese Circulation Society 25.07.2016
Subjects
Aged
Female
Heart Arrest - physiopathology
Heart Arrest - therapy
Humans
Hydrogen - administration & dosage
Hydrogen - adverse effects
Hydrogen gas inhalation
Male
Middle Aged
Molecular hydrogen
Pilot Projects
Post-cardiac arrest syndrome
Prospective Studies
Return of spontaneous circulation
Online AccessGet full text

Cover

More Information
Summary:Background:Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of post-cardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied.Methods and Results:Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. After excluding 16 patients with specific criteria, 5 patients underwent HI together with target temperature management (TTM). No undesirable effects attributable to HI were observed and 4 patients survived 90 days with a favorable neurological outcome.Conclusions:HI in combination with TTM is a feasible therapy for patients with PCAS. (Circ J 2016; 80: 1870–1873)
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1346-9843
1347-4820
DOI:10.1253/circj.CJ-16-0127